{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:07:38Z","timestamp":1762002458956,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12032-018-1093-8","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T08:14:30Z","timestamp":1518509670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3780-5331","authenticated-orcid":false,"given":"Michihide","family":"Tokuhira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia"},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252\u201365.","journal-title":"Am J Hematol"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","volume":"32","author":"J Francis","year":"2015","unstructured":"Francis J, Dubashi B, Sundaram R, Pradhan SC, Chandrasekaran A. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1\u00a0year in chronic myeloid leukemia patients treated with imatinib. Med Oncol. 2015;32:213.","journal-title":"Med Oncol"},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585\u201390.","journal-title":"Leuk Res"},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12185-008-0186-0","volume":"88","author":"M Kizaki","year":"2008","unstructured":"Kizaki M, Okamoto S, Tauchi T, Tanaka H, Tanimoto M, Inokuchi K, et al. Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH. Int J Hematol. 2008;88:409\u201317.","journal-title":"Int J Hematol"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30:57\u201364.","journal-title":"Leukemia"},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3324\/haematol.2016.144949","volume":"101","author":"F Castagnetti","year":"2016","unstructured":"Castagnetti F, Breccia M, Gugliotta G, Martino B, D\u2019Adda M, Stagno F, et al. Nilotinib 300\u00a0mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica. 2016;101:1200\u20137.","journal-title":"Haematologica"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.clml.2015.06.006","volume":"15","author":"NJ Bella Di","year":"2015","unstructured":"Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, et al. The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting. Clin Lymphoma Myeloma Leuk. 2015;15:599\u2013605.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","volume":"37","author":"HJ Henk","year":"2015","unstructured":"Henk HJ, Woloj M, Shapiro M, Whiteley J, et al. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37:124\u201333.","journal-title":"Clin Ther"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S, Jabbour E, Konopleva M, Ferrajoli A, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117:3733\u20136.","journal-title":"Blood"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12032-017-0958-6","volume":"34","author":"A Rychter","year":"2017","unstructured":"Rychter A, Jerzmanowski P, Ho\u0142ub A, Specht-Szwoch Z, Kalinowska V, T\u0119gowska U, et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol. 2017;34:104.","journal-title":"Med Oncol"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","volume":"17","author":"H Itamura","year":"2017","unstructured":"Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S, et al. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20\u00a0mg. Clin Lymphoma Myeloma Leuk. 2017;17:370\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2017.01.003","volume":"54","author":"N Iriyama","year":"2017","unstructured":"Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K, Fujita H, et al. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML Cooperative Study Group. Leuk Res. 2017;54:55\u20138.","journal-title":"Leuk Res"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1387907","volume":"25","author":"E Sato","year":"2017","unstructured":"Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European Treatment and Outcome Study (EUTOS) score. Leuk Lymphoma. 2017;25:1\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Cervantes F, Clark RE, Cortes JE, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"1093_CR25","first-page":"481","volume":"50","author":"F Yagasaki","year":"2009","unstructured":"Yagasaki F, Niwa T, Abe A, Ishikawa M, Kato C, Ogura K, et al. Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki. 2009;50:481\u20137.","journal-title":"Rinsho Ketsueki"},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2010","unstructured":"Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010;87:197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","volume":"4","author":"RE Clark","year":"2017","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4:e310\u20136.","journal-title":"Lancet Haematol"},{"key":"1093_CR29","unstructured":"Rea D, Cayuela J-M, Dulucq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). In: 2017 ASH meeting, oral presentation, #380. 2017."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1093-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:28:47Z","timestamp":1550017727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1093-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1093-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"30 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MT received honoraria from Pfizer Inc. and Bristol-Myers Squibb. TT, NI, YH, MK, and TK received honoraria from Bristol-Myers Squibb and Novartis Pharma K.K. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies were in accordance with the ethical standards of each institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"38"}}